A long-term (twelve months) multicenter trial evaluated the dialytic efficiency, clinical tolerance and biocompatibility (complement activation, granulocyte elastase, IL-2 soluble receptor and beta 2 microglobulin) of paired filtration dialysis (PFD), a hemodiafiltration technique that uses both convection and diffusion, with a double chamber hemodialyzer composed of high-flux polysulfone (0.55 sqm) and Hemophan (1.36 sqm), a modified cellulose membrane. Twenty-five chronic stable dialytic patients were studied for six months using their previous standard dialytic treatment (control study period) and then switched to PFD for one year (PFD study period). PFD resulted in a urea Kt/V over 1.1, high beta 2-microglobulin removal (120 mg/treatment), shorter dialysis time (180 versus 210 min) and better clinical tolerance. Although PFD caused a small degree of complement activation, granulocyte elastase plasma release and interleukin-2 soluble receptor, the levels were comparable to those obtained with synthetic membranes, even if modified cellulose was employed in the SG3 hemodialyzer, suggesting improved biocompatibility. Specific immunochemical analysis at the end of treatment showed that the proteins adsorbed were minimal when Hemophan was used in the PFD configuration, The possible mechanisms of this improved biocompatibility are discussed.
PAIRED FILTRATION DIALYSIS (PFD) - BIOCOMPATIBILITY, DIALYTIC EFFICIENCY AND CLINICAL TOLERANCE IN A LONG-TERM MULTICENTER TRIAL
PANICHI, VINCENZO;
1995-01-01
Abstract
A long-term (twelve months) multicenter trial evaluated the dialytic efficiency, clinical tolerance and biocompatibility (complement activation, granulocyte elastase, IL-2 soluble receptor and beta 2 microglobulin) of paired filtration dialysis (PFD), a hemodiafiltration technique that uses both convection and diffusion, with a double chamber hemodialyzer composed of high-flux polysulfone (0.55 sqm) and Hemophan (1.36 sqm), a modified cellulose membrane. Twenty-five chronic stable dialytic patients were studied for six months using their previous standard dialytic treatment (control study period) and then switched to PFD for one year (PFD study period). PFD resulted in a urea Kt/V over 1.1, high beta 2-microglobulin removal (120 mg/treatment), shorter dialysis time (180 versus 210 min) and better clinical tolerance. Although PFD caused a small degree of complement activation, granulocyte elastase plasma release and interleukin-2 soluble receptor, the levels were comparable to those obtained with synthetic membranes, even if modified cellulose was employed in the SG3 hemodialyzer, suggesting improved biocompatibility. Specific immunochemical analysis at the end of treatment showed that the proteins adsorbed were minimal when Hemophan was used in the PFD configuration, The possible mechanisms of this improved biocompatibility are discussed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
